Media event: |
Leading medical experts and patients who are living with atrial fibrilation provide insight into the limitations of current anticoagulation therapy and the impact this has on patients, carers and doctors. Further an update on the development of dabigatran etexilate and its potential to transform stroke prevention and other important therapy areas is given. |
|---|---|
Venue: |
Boehringer Ingelheim Corporate Headquarters, Ingelheim, Germany
|


















